BioCryst Pharmaceuticals (NASDAQ:BCRX) Receives "Outperform" Rating from Royal Bank Of Canada

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report)'s stock had its "outperform" rating reaffirmed by stock analysts at Royal Bank Of Canada in a research note issued to investors on Monday,Benzinga reports. They presently have a $13.00 price objective on the biotechnology company's stock. Royal Bank Of Canada's price target points to a potential upside of 45.09% from the stock's current price.

Other analysts have also recently issued research reports about the stock. Cantor Fitzgerald started coverage on shares of BioCryst Pharmaceuticals in a research note on Tuesday, April 29th. They set an "overweight" rating and a $20.00 target price for the company. Wall Street Zen cut BioCryst Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Saturday. Needham & Company LLC reissued a "buy" rating and set a $17.00 target price on shares of BioCryst Pharmaceuticals in a report on Wednesday, June 25th. Barclays lifted their price target on BioCryst Pharmaceuticals from $8.00 to $11.00 and gave the stock an "equal weight" rating in a research note on Wednesday, May 7th. Finally, HC Wainwright reissued a "buy" rating and issued a $30.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Tuesday, May 6th. One investment analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $16.89.

BioCryst Pharmaceuticals Price Performance

BCRX stock traded down $0.40 during trading on Monday, hitting $8.96. 5,123,797 shares of the company traded hands, compared to its average volume of 3,028,499. BioCryst Pharmaceuticals has a 1 year low of $6.02 and a 1 year high of $12.50. The company has a market cap of $1.87 billion, a PE ratio of -34.46, a P/E/G ratio of 1.87 and a beta of 1.10. The stock's 50-day simple moving average is $9.96 and its 200 day simple moving average is $8.56.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of BCRX. Millennium Management LLC increased its position in BioCryst Pharmaceuticals by 382.6% during the first quarter. Millennium Management LLC now owns 3,812,874 shares of the biotechnology company's stock worth $28,597,000 after purchasing an additional 3,022,769 shares during the last quarter. Vanguard Group Inc. raised its position in shares of BioCryst Pharmaceuticals by 7.8% during the 4th quarter. Vanguard Group Inc. now owns 21,890,422 shares of the biotechnology company's stock valued at $164,616,000 after buying an additional 1,583,826 shares during the period. Eversept Partners LP raised its position in shares of BioCryst Pharmaceuticals by 269.9% during the 4th quarter. Eversept Partners LP now owns 1,980,312 shares of the biotechnology company's stock valued at $14,892,000 after buying an additional 1,444,907 shares during the period. Nuveen LLC acquired a new position in BioCryst Pharmaceuticals in the first quarter valued at approximately $10,677,000. Finally, Jupiter Asset Management Ltd. grew its position in BioCryst Pharmaceuticals by 82.4% in the first quarter. Jupiter Asset Management Ltd. now owns 2,148,969 shares of the biotechnology company's stock worth $16,117,000 after acquiring an additional 971,040 shares during the period. Institutional investors and hedge funds own 85.88% of the company's stock.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.